Peptide-based targeted cancer therapeutics: Design, synthesis and biological evaluation

Area of Science:

• Oncology
• Drug Discovery
• Biochemistry

Background:

• Abl tyrosine kinases are crucial in cancer cell proliferation and survival.
• Targeting Abl kinases is a key strategy in developing novel cancer therapeutics.
• Existing treatments like Imatinib and Nilotinib highlight Abl as a viable drug target.

Purpose of the Study:

• To design, synthesize, and evaluate novel lysine-based oligopeptides for Abl tyrosine kinase inhibition.
• To assess the anticancer potential of these peptides against various cancer cell lines.
• To identify specific peptide candidates with significant antiproliferative and anti-migration effects.

Main Methods:

• Solid-phase peptide synthesis (SPPS) using Fmoc chemistry.
• High-Performance Liquid Chromatography (HPLC) for purification and Mass Spectrometry (MS) for analysis.
• In vitro biological testing including cytotoxicity, apoptosis induction, and migration assays on CML, breast, and glioblastoma cell lines.
• Molecular docking simulations using AutoDock Vina to predict Abl binding.

Main Results:

• Synthesized oligopeptides demonstrated concentration-dependent antiproliferative effects across tested cancer cell lines.
• One specific peptide, H-Lys¹-Lys²-Lys³-NH₂, showed significant inhibition of migration in U87 glioblastoma cells.
• Peptides exhibited varying levels of cytotoxic and apoptotic effects in cancer cell lines.

Conclusions:

• Lysine-based oligopeptides represent a promising class of compounds for targeting Abl tyrosine kinases.
• The identified peptide H-Lys¹-Lys²-Lys³-NH₂ warrants further investigation for its anti-migratory properties in glioblastoma.
• These findings support the development of peptide-based drugs for cancer treatment.